Cyclononyl-methylamin | 4744-73-4

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: Cyclononyl-methylamin
• 英文别名: Cyclononylmethanamine
• CAS: 4744-73-4
• 化学式: C₁₀H₂₁N
• 分子量: 155.283
• InChiKey: JADWQTWGYPELAQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  26
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  cyclononylamide 在 lithium aluminium tetrahydride 作用下， 以 乙醚 为溶剂， 生成 Cyclononyl-methylamin
  参考文献：
  名称：

  Amine Oxides. VIII. Medium-sized Cyclic Olefins from Amine Oxides and Quaternary Ammonium Hydroxides^1,2

  摘要：

  Thermal decompositions of the N-oxides derived from N,N-dimethyl-1-methylcycloalk,lamines II having eight-, nine- and ten-membered rings yield olefin mixtures containing 98.6, 94.0 and 97.5%, respectively, of 1-methylcycloalkenes. Considerable amounts of the trans isomers are formed from the nine- and ten-membered N-oxides. Pyrolyses of the corresponding quaternary hydroxides produce mixtures of methylenecycloalkanes and 1-methylcycloalkenes (predominantly cis), violation of the Hofmann rule being at a maximum in the decomposition of the nine-membered quaternary hydroxide. Importance of relative product stabilities and the operation of non-bonded interactions are discussed as possible explanations for the observed directions of elimination. Thermal decompositions of the N-oxides and quaternary hydroxides of dimethylcycloalkvimethylamines IV containing eight-, nine- and ten-membered rings proceed as expected with formation of the corresponding methylenecycloalkanes.

  DOI：

  10.1021/ja01502a053

文献信息

• Pyrrolo[2,3-d]pyrimidine compounds
  申请人：——

  公开号：US20020019526A1

  公开（公告）日：2002-02-14

  A compound of the formula 1 wherein R 1 , R 2 and R 3 are as defined above, which are inhibitors of the enzyme protein tyrosine kinases such as Janus Kinase 3 and as such are useful therapy as immunosuppressive agents for organ transplants, lupus, multiple sclerosis, rheumatoid arthritis, psoriasis, Type I diabetes and complications from diabetes, cancer, asthma, atopic dermatitis, autoimmune thyroid disorders, ulcerative colitis, Crohn's disease, Alzheimer's disease, Leukemia and other autoimmune diseases.

  一种化合物的结构式，其中R1、R2和R3如上所定义，它们是蛋白酪氨酸激酶的抑制剂，如Janus激酶3，因此可作为免疫抑制剂用于器官移植、狼疮、多发性硬化、类风湿性关节炎、牛皮癣、1型糖尿病和糖尿病并发症、癌症、哮喘、特应性皮炎、自身免疫性甲状腺疾病、溃疡性结肠炎、克罗恩病、阿尔茨海默病、白血病和其他自身免疫疾病的治疗。
• [EN] BENZENESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF<br/>[FR] DÉRIVÉS DE BENZÈNESULFONAMIDE EN TANT QUE MODULATEURS TRAP1 ET UTILISATIONS ASSOCIÉES
  申请人：AMATHUS THERAPEUTICS INC

  公开号：WO2021188880A1

  公开（公告）日：2021-09-23

  The present disclosure provides compounds of Formula (I): and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled compounds, and prodrugs thereof. The provided compounds may be tumor necrosis factor ("TNF") receptor associated protein 1 ("TRAP1") modulators (e.g., TRAP1 activators). The provided compounds may also rescue the activity in PTEN-induced kinase 1 ("PINK1") loss of function contexts. The provided compounds may also improve mitochondrial health, function, quality, quantity, and/or activity, and/or reduce the production of reactive oxygen species. The provided compounds may also refold or solubilize aggregated or misfolded proteins such as α-synuclein. The present disclosure also provides pharmaceutical compositions comprising the provided compounds; kits comprising the provided compounds or pharmaceutical compositions; and methods of using the provided compounds and pharmaceutical compositions (e.g., for treating a disease in a subject in need thereof).

  本公开提供了Formula (I)的化合物及其药用盐、溶剂化合物、水合物、多晶形态、共晶体、互变异构体、立体异构体、同位素标记化合物和其前药。所提供的化合物可能是肿瘤坏死因子（"TNF"）受体相关蛋白1（"TRAP1"）调节剂（例如，TRAP1激活剂）。所提供的化合物还可能在PTEN诱导激酶1（"PINK1"）功能丧失的情况下恢复活性。所提供的化合物还可能改善线粒体的健康、功能、质量、数量和/或活性，并/或减少活性氧自由基的产生。所提供的化合物还可能对α-突触核蛋白等聚集或错误折叠的蛋白进行重新折叠或溶解。本公开还提供了包含所提供化合物的药物组合物；包含所提供化合物或药物组合物的试剂盒；以及使用所提供化合物和药物组合物的方法（例如，用于治疗需要的受试者的疾病）。
• Non-specific reaction inhibitor, method for inhibiting non-specific reaction, and kit
  申请人：Okamura Yoshikazu

  公开号：US11125742B2

  公开（公告）日：2021-09-21

  Provided is a non-specific reaction inhibitor for achieving the accurate detection and quantitation of a trace component (a target substance) contained in a sample, in an immunoassay, by simply and effectively inhibiting a non-specific reaction associated with the measurement. The non-specific reaction inhibitor comprises a substance of the formula I: wherein R1 and R2 together form a double bond between carbons, to which they are respectively bonded directly, or R1 is a hydrogen atom and R2 is a group formed by removing H from an SH-group-containing compound, B is a support, and L is a spacer arm portion.

  提供的是一种非特异性反应抑制剂，用于通过简单有效地抑制与测量相关的非特异性反应，在免疫测定中实现对样品中微量组分（目标物质）的准确检测和定量。该非特异性反应抑制剂包括式I的物质：其中R1和R2共同形成碳之间的双键，它们分别直接连接在碳上，或者R1是氢原子，R2是从含有SH基团的化合物中去除H形成的基团，B是支持体，L是空间臂部分。
• Pyrrolo [2,3-D] pyrimidine compounds
  申请人：Pfizer Inc.

  公开号：US20030212273A1

  公开（公告）日：2003-11-13

  A compound of the formula 1 wherein R 1 , R 2 and R 3 are as defined above, which are inhibitors of the enzyme protein tyrosine kinases such as Janus Kinase 3 and as such are useful therapy as immunosuppressive agents for organ transplants, lupus, multiple sclerosis, rheumatoid arthritis, psoriasis, Type I diabetes and complications from diabetes, cancer, asthma, atopic dermatitis, autoimmune thyroid disorders, ulcerative colitis, Crohn's disease, Alzheimer's disease, Leukemia and other autoimmune diseases.

  化合物的公式为1，其中R1，R2和R3的定义如上所述，它们是蛋白酪氨酸激酶的抑制剂，例如Janus Kinase 3，并且作为免疫抑制剂用于器官移植，狼疮，多发性硬化症，类风湿性关节炎，牛皮癣，1型糖尿病和糖尿病并发症，癌症，哮喘，特应性皮炎，自身免疫性甲状腺疾病，溃疡性结肠炎，克罗恩病，阿尔茨海默病，白血病和其他自身免疫性疾病的有用治疗方法。
• METHOD FOR PRODUCING POLYMER COMPOUND
  申请人：Sumitomo Chemical Company, Limited

  公开号：EP3636690A1

  公开（公告）日：2020-04-15

  An object of the present invention is to provide a method for producing a polymer compound having a crosslinkable group, the polymer compound having a low content of low-molecular-weight compounds and sufficiently low polydispersity. The method for producing a polymer compound having a crosslinkable group comprises the steps of: (1) polymerizing a monomer component in a solvent in the presence of a transition metal complex to thereby obtain a first polymer compound having a crosslinkable group, wherein the monomer component comprises a monomer having a crosslinkable group; and (2) mixing a solution containing a first solvent and the first polymer compound with a second solvent, followed by separation into two or more layers, and selecting a layer containing a polymer compound having the largest polystyrene-equivalent weight average molecular weight to thereby obtain a second polymer compound having a crosslinkable group, wherein the first solvent contains a solvent of the same kind as the solvent used in step (1), the second solvent is a poor solvent for the first polymer compound, and the solvent contained in each of the two or more layers is substantially an organic solvent.

  本发明的目的是提供一种生产具有可交联基团的聚合物化合物的方法，该聚合物化合物具有较低的低分子量化合物含量和足够低的多分散性。生产具有可交联基团的聚合物化合物的方法包括以下步骤：(1) 在过渡金属复合物存在下，在溶剂中聚合单体组分，从而获得第一种具有可交联基团的聚合物化合物，其中单体组分包括具有可交联基团的单体；(2) 将含有第一种溶剂和第一种聚合物化合物的溶液与第二种溶剂混合，然后分离成两层或多层，并选择含有聚苯乙烯当量重平均分子量最大的聚合物化合物的一层，从而得到具有可交联基团的第二种聚合物化合物，其中第一种溶剂含有与步骤(1)中所用溶剂相同种类的溶剂，第二种溶剂是第一种聚合物化合物的劣溶剂，两层或多层中每一层所含的溶剂基本上是有机溶剂。